CytomX Therapeutics
CTMX
60 hedge funds and large institutions have $193M invested in CytomX Therapeutics in 2016 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 6 reducing their positions, and 6 closing their positions.
367% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 6
200% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 6
22% more funds holding
Funds holding: 49 → 60 (+11)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
16% less capital invested
Capital invested by funds: $228M → $193M (-$35.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$6.16M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$4.88M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.77M |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$2.51M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$9.66M |
| 2 |
CPI
Canaan Partners IX
Menlo Park,
California
|
-$7.3M |
| 3 |
CC
Casdin Capital
New York
|
-$990K |
| 4 |
GC
Globeflex Capital
San Diego,
California
|
-$761K |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$591K |
CTMX Hedge Fund Activity: Q2 2016 in Review
60 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2016, worth a combined $193M — down 16% from $228M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CTMX positions and 6 closed out — a net gain of 12 holders — while 28 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock Advisors, adding an estimated $6.16M. The largest seller was Wellington Management Group, exiting entirely with an estimated $9.66M sold.
- 60 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2016, up from 49 in Q1 2016.
- Funds reported $193M of CytomX Therapeutics stock for Q2 2016, down 16% quarter-over-quarter.
- 18 funds opened new CytomX Therapeutics positions in Q2 2016 and 6 closed out, a net change of +12 holders.
- The largest CytomX Therapeutics buyer in Q2 2016 was BlackRock Advisors, an estimated $6.16M added.
- The largest CytomX Therapeutics seller in Q2 2016 was Wellington Management Group, an estimated $9.66M sold.
Based on aggregated 13F filings for Q2 2016.